Uncontrol trial of targeted therapy on chronic glomerulonephritis

Uncontrol trial of targeted therapy on chronic glomerulonephritis - Uncontrol trial of targeted therapy on chronic glomerulonephritis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006080

Enrollment

Registered

2011-08-01

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic glomerulonephritis

Interventions

Rituximab 375mg/2 once a week total 4 times, tocilizumab 8 mg/kg once a month total 3 times, or abatacept 500mg once a month total 7 times, 24 months follow-up

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic glomerulonephritis on biopsy, rebellant, patients with participation after written informed concent

Exclusion criteria

Exclusion criteria: Patients with positive serology for hepatitis B, C or HIV, severe renal dysfunction, severe liver dysfunction, pregnant woman

Design outcomes

Primary

Measure	Time frame
urinalysis, the cumulative dose of prednisolone and the cumulative dose of immunosuppressive drugs	—

Secondary

Measure	Time frame
the adverse effects of prednisolone, the adverse effects of immunosuppressive drugs, the adverse effects of targeted therapy	—

Countries

Japan

Contacts

Public ContactTatsuo Hashimoto

Yokohama City University Hospital Department of Nephrology and Hypertension

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026